Starpharma Holdings Ltd. and AstraZeneca have entered an agreement under which AstraZeneca will test certain Starpharma oncology molecules based on Starpharma’s dendrimer technology. AstraZeneca will conduct studies using specific Starpharma drug-dendrimer conjugate molecules and assess the suitability of the dendrimer constructs for applications in the cancer field.
Neither the molecules to be studied nor further details of the agreement were disclosed.
Starpharma, AstraZeneca In Discovery Alliance
Published September 7, 2012
blog comments powered by Disqus